Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (13551)	1/21/1998 12:43:00 AM
From: DrJerry	Read Replies (2) \| Respond to of 32384

Henry: Thanks for the info re: IR and LGNDW. Despite the huge market-cap the scuttlebut around here is that WLA may be next in the merger-acquisition line. The WLA people clearly admit that they "goofed" re: a deal with LGND and although they are very confident of Rezulin's continued growth in sales they have no further near term diabetic synergists (such as rexinoids). It would be a real "hoot" if there was a Glaxo-WLA deal since everyone is convinced that Glaxo's pull of Rezulin in the UK was purely an attempt to gain marketshare for its upcoming TZD drug. It seems the NYTimes article was a big boost for promoting general knowledge of LGND although I would have hoped for greater volume in trades today.